Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications T-Cells

Publication Date: January 28, 2025

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

Autologous, rapamycin-resistant Th1/Tc1 T cells (RAPA-201) induced remission in 9 of 14 patients with relapsed, refractory multiple myeloma, without any adverse event attributable to the cell product. Lymphocytes from steady-state apheresis were cultured for one week with high-dose temsirolimus, pegylated IFN-alpha-2b, IL-7 and IL-15, and every patient's product was manufactured without failure. Compared with input cells, the products were enriched for naïve and central memory T cells and showed lower PD1, CD73 and LAIR1 expression. Patients received a median of three outpatient infusions at a median dose of 80 × 10^6 cells after low-intensity cyclophosphamide, with or without pentostatin…

Download Now →

Author: Binod Dhakal, Parameswaran Hari +9 more

Publications TCR T Cells G-Rex®24 Well Plate

Publication Date: January 23, 2025

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients

A T cell receptor targeting the KRAS G12V8–16 neoepitope on HLA-A*11:01 was isolated from a pancreatic cancer patient's blood and showed high specificity, but modest activity against patient-derived organoids. Sequential in vitro peptide stimulation of PBMCs from 6 HLA-A*11:01-positive patients with KRAS G12V tumors revealed reactive CD8 T cells in one patient and HLA-DRB1*15:01-restricted CD4 T cells in another. T cells carrying the TCR recognized all 5 tested organoids, often modestly, but killed only 2 (PDAC-59 and PAC-229). Priming organoids with IFN-γ, but not IFN-α2b, improved recognition and killing, and the engineered T cells slowed growth of PDAC-59 xenografts in immunodeficient…

Download Now →

Author: Xiongfei Xu, Shiwei Guo +19 more

Publications NKT Cells G-Rex®6 Well Plate

Publication Date: January 16, 2025

PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function

A pooled CRISPR/Cas9 screen of 1,118 immune-related genes in human NKT cells identified PRDM1 as a regulator of central memory differentiation and effector function. Unmodified NKTs and GD2.CAR NKTs were challenged with tumor cells for six rounds, and PRDM1 guide RNAs were enriched in both. The CAR-positive fraction in PRDM1 knockout cells rose from 30.63% to 88.11%. PRDM1 knockout raised CD62L expression and lowered PD-1, but reduced granzyme B and cytotoxicity, giving only a modest survival gain in neuroblastoma-bearing mice. Short hairpin RNA knockdown of PRDM1 kept cytotoxicity while raising CD62L, and these GD2.CAR NKTs controlled tumor, extended survival and persisted more in liver,…

Download Now →

Author: Gengwen Tian, Gabriel A. Barragan +14 more

Publications TIL Cells G-Rex®100M

Publication Date: January 10, 2025

Characteristics of successful expansion of tumor-infiltrating lymphocytes from colorectal cancer liver metastasis

Tumor-infiltrating lymphocytes (TILs) were successfully expanded from all 15 colorectal cancer liver metastases, and a higher Klintrup–Mäkinen (KM) score for inflammation at the invasive margin was associated with larger TIL yields. Tumor fragments of 1–2 mm were cultured for 14 days with 1,000 IU/mL IL-2, yielding a mean 2.59 × 10^5 TILs per fragment and 167.79 × 10^5 per case. Five cases then underwent rapid expansion in G-rex 100 M flasks with irradiated allogeneic PBMCs, OKT3 and IL-2, reaching a median 3,610-fold expansion. The median CD8+ fraction rose from 19.8% to 44.7% during this step. KM score correlated with initially expanded TIL numbers (R = 0.701, p = 0.004), whereas stroma…

Download Now →

Author: Jina Baek, Gyuheon Choi +7 more

Publications NK Cells G-Rex®100M

Publication Date: January 9, 2025

Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications

A magnetic negative-selection and feeder-based protocol isolates natural killer cells from human peripheral blood and expands them to numbers relevant for clinical use. Starting from 25 ml of blood, isolation yielded on average 3.1 × 10^6 NK cells, with over 90% viability and close to 99% CD3-CD56+ purity. Cultures received irradiated EBV-LCL feeder cells at a 1:10 NK:feeder ratio, a single dose of 20 ng/ml IL-21 and repeated additions of 500 IU/ml IL-2. Seeding 2 × 10^6 NK cells gave an average of 1.89 × 10^11 cells by day 28, and cytotoxicity against K562 targets was maintained from day 12 to day 28 and after cryopreservation. The method was also tested in G-Rex® 100M flasks to assess s…

Download Now →

Author: Soumyadipta Kundu, Leonie Durkan +2 more

Publications NK Cells G-Rex®24 Well Plate

Publication Date: January 6, 2025

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

Human natural killer cells transiently engineered with mRNA to express an EphA2-targeted chimeric antigen receptor killed paediatric sarcoma cells more effectively than unmodified NK cells. Electroporation with a MaxCyte STx system gave higher CAR expression than lipid nanoparticle delivery. Of three scFv clones tested, 4H5 was the most effective, and killing of rhabdomyosarcoma lines depended on EphA2, as EphA2-knockout cells were spared. Adding 10% ATPαS to m1Ψ mRNA increased eGFP intensity across 168 hours in HEK293F cells. In immunodeficient mice, EphA2-CAR-NK cells suppressed local rhabdomyosarcoma progression, reduced lung metastasis, and inhibited osteosarcoma growth with a surviva…

Download Now →

Author: Pui Yeng Lam, Natacha Omer +21 more

Publications T-Cells

Publication Date: January 2, 2025

Enrichment of CD4+ and CD8+ T lymphocytes with a column-free flow-based device for clinical cell manufacturing

MARS Bar, a column-free, flow-based and fully closed magnetic selection platform, enriched CD4+ and CD8+ T cells from human leukopaks with high purity in under an hour of run time. With quarter leukopaks of about 2.5 × 10^9 cells, CD3+ purity reached 95.51% for fresh and 93.13% for thawed product, and CD3+ recovery was 64.68% and 57.06%. The selection step lasted 39 to 55 minutes. Adding automated LOVO washing in place of manual centrifugation gave total processing of about 130 minutes, with post-selection CD3+ purity of 96.8% in buffer and 95.8% in T-cell medium and CD3+ recovery of 71.0% in buffer. Runs were done at two sites using few leukopaks.

Download Now →

Author: Paulina Langa, Kriti Sharma +11 more

Publications CTL Cells

Publication Date: January 1, 2025

Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same Device as Antigen Presenting Cells (APC) for the Production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the Same Device

Monocyte-derived dendritic cells and tumor-associated antigen-specific T cells (TAAT) can be produced one after the other in a single GREX device, avoiding the harvest of adherent dendritic cells. Monocytes seeded at 0.25–0.5e6 cells/cm² were differentiated with GM-CSF/IL-4, loaded with PRAME, Survivin and WT1 peptides, and matured; PBMC were then added directly at a 1:5 to 1:10 ratio and expanded for 14 days. Dendritic cell yield was 43.1% of starting monocytes. T cells expanded 11.33-fold by day 14, with 27.49% IFNg-positive upon restimulation versus 11.98% in negative control. By day 28 expansion reached 257.85-fold. Thirty milliliters of blood yielded 50.83e6 TAAT by day 14, suggestin…

Download Now →

Author: Dmitrii Vozniuk, Maria Dontsova +19 more

Publications DC Cells, T-Cells

Publication Date: January 1, 2025

Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same Device as Antigen Presenting Cells (APC)

Monocyte-derived dendritic cells can be manufactured in a closed GREX culture vessel and the same device can then be used to prime tumor-associated antigen-specific T cells (TAAT). Monocytes isolated by CD14 selection from 30 mL of blood were differentiated with GM-CSF and IL-4, loaded with PRAME, Survivin and WT1 peptides, and matured with TNF-a, IL-6, IL-1b and PGE2 (n = 7). A 4-day protocol gave a yield of 48.3% of starting monocytes versus 30.0% for the 7-day protocol, with similar maturation markers. Priming donor PBMC produced an 11.33-fold expansion, and 30.45% of antigen-stimulated T cells were IFNg+ after restimulation versus 13.8% in controls. A 30 mL blood draw yielded 50.83e6…

Download Now →

Author: Dmitrii Vozniuk, Maria Dontsova +19 more

Publications CAR T Cells

Publication Date: January 1, 2025

Optimization of Transduction step

Coating the G-Rex® membrane with RetroNectin allows T cell activation and lentiviral transduction to occur simultaneously, giving a simple CAR-T manufacturing method. CAR-T cells grown in RetroNectin-coated G-Rex® proliferated faster and stayed more undifferentiated than in uncoated conditions, with both CD3/CD28 bead and RetroNectin/anti-CD3 stimulation. Transduction efficiency ranked RetroNectin/OKT3 above RetroNectin plus beads above beads alone, and RetroNectin achieved higher efficiency at low MOI. Day 0 transduction on RetroNectin coatings was comparable to Day 1 infection efficiency. Cytotoxicity followed the same order. In vivo, CAR-T cells made by the Spo-T method kept strong ant…

Download Now →

Author: Yasunori Amaishi, Izumi Maki +4 more

Publications CD34 Cells

Publication Date: January 1, 2025

Iterative Process Development of an HDR Gene Edited HSPC Drug Product to Treat Sickle Cell Disease

This presentation details the process development (V2.0) for nula-cel, a gene-edited HSPC product for Sickle Cell Disease. G-Rex® were implemented for cell culture, improving cell health and scalability compared to the V1.0 process. The optimized process showed improved engraftment and editing efficiency.

Download Now →

Author: Jason Skowronski

Publications CAR T Cells, Other G-Rex®24 Well Plate, G-Rex®6M Well Plate

Publication Date: January 1, 2025

Efficient and rapid GMP-scalable production of CAR-T and CIK cells

CAR-T cells and cytokine-induced killer (CIK) cells grown from healthy-donor blood mononuclear cells expanded with high, comparable yield and viability in G-Rex® gas-permeable devices at two culture scales, keeping a similar phenotype and killing activity at both. CAR-T cells were activated with anti-CD3/CD28 antibodies, lentivirally transduced, cultured with IL-7 and IL-15 and collected on day 9. CIK cells were stimulated with interferon-γ, anti-CD3 antibody and IL-2 and collected on day 14. Flow cytometry tracked transduction, CD4/CD8 composition and memory status, plus CD3+CD56+ and NKG2D expression in CIK cells. CAR-T cells killed Raji lymphoma cells in a 6-hour assay, and CIK cells k…

Download Now →

Author: Sara Boscarato, Giulia D’Accardio +6 more